Thomas G Lauridsen
Overview
Explore the profile of Thomas G Lauridsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vrist M, Ostergaard A, Langaa S, Mose F, Fynbo C, Theil J, et al.
Am J Nephrol
. 2022 Jun;
53(6):490-502.
PMID: 35671711
Introduction: Invasive bone biopsy to assess bone metabolism in patients with chronic kidney disease-mineral and bone disorder may be replaced by the noninvasive 18F-NaF PET/CT and biomarkers of bone metabolism....
2.
Hornstrup B, Gjoerup P, Wessels J, Lauridsen T, Pedersen E, Bech J
Int J Nephrol Renovasc Dis
. 2018 Dec;
11:279-290.
PMID: 30510439
Background: Chronic kidney disease (CKD) is often associated with a blunted nocturnal BP decrease and OSA. However, it is not fully clear whether a relationship exists between reduction in renal...
3.
Matthesen S, Larsen T, Vase H, Lauridsen T, Jensen J, Pedersen E
Clin Exp Hypertens
. 2012 Sep;
35(5):313-24.
PMID: 22966789
This study demonstrates that the increased potassium content in the body seems to change both the blood pressure and renal tubular function. We wanted to test the hypotheses that amiloride...
4.
Matthesen S, Larsen T, Vase H, Lauridsen T, Pedersen E
Scand J Clin Lab Invest
. 2011 Dec;
72(1):78-86.
PMID: 22149452
Background: Potassium is the main intracellular cation, which contributes to keeping the intracellular membrane potential slightly negative and elicits contraction of smooth, skeletal and cardiac muscle. A change in potassium...
5.
Hansen D, Rasmussen K, Danielsen H, Meyer-Hofmann H, Bacevicius E, Lauridsen T, et al.
Kidney Int
. 2011 Aug;
80(8):841-50.
PMID: 21832979
Alfacalcidol and paricalcitol are vitamin D analogs used for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease, but have known dose-dependent side effects that cause hypercalcemia and...
6.
Vase H, Lauridsen T, Graffe C, Pedersen E
J Am Soc Hypertens
. 2011 Jun;
5(5):385-94.
PMID: 21640689
AT(1) receptor antagonists possess sympathoinhibitory effects in animal experiments, but in human studies the results are conflicting. We tested the hypothesis that very short-term treatment with the AT(1) receptor antagonist...
7.
Lauridsen T, Vase H, Starklint J, Graffe C, Bech J, Nielsen S, et al.
BMC Nephrol
. 2010 Oct;
11:28.
PMID: 21029429
Background: Treatment with prostaglandin inhibitors can reduce renal function and impair renal water and sodium excretion. We tested the hypotheses that a reduction in prostaglandin synthesis by ibuprofen treatment during...
8.
Pedersen E, Thomsen I, Lauridsen T
BMC Nephrol
. 2010 Oct;
11:26.
PMID: 20923561
Background: The kidneys ability to concentrate and dilute urine is deteriorated during progressive renal insufficiency. We wanted to test the hypothesis that these phenomena could be attributed to an abnormal...
9.
Lauridsen T, Vase H, Bech J, Nielsen S, Pedersen E
Eur J Endocrinol
. 2010 Mar;
162(5):961-9.
PMID: 20203161
Background: Glucocorticoids influence renal concentrating and diluting ability. We tested the hypothesis that methylprednisolone treatment increased renal water and sodium absorption by increased absorption via the aquaporin-2 (AQP2) water channels...
10.
Vase H, Lauridsen T, Bech J, Pedersen E
Br J Clin Pharmacol
. 2008 Mar;
65(6):822-32.
PMID: 18341678
What Is Already Known About This Subject: A sympatho-inhibitory effect of ACE-inhibitors and AT(1) receptor antagonists has been widely demonstrated in animal models, but in humans this effect tends only...